Form 4: AIM ImmunoTech Director Acquires Shares as Part of Compensation Plan

Director Stewart Appelrouth acquired 22,645 shares of AIM ImmunoTech stock as part of a compensation plan.

Summary

• Stewart Appelrouth, a director at AIM ImmunoTech Inc., acquired 22,645 shares of common stock on December 2, 2024.
• The shares were acquired at a price of $0.23 per share.
• This transaction increased Appelrouth's total direct holdings to 344,397 shares.
• The shares were issued in lieu of director compensation under the company's Cash Conservation Plan.

Sentiment

Score: 7

Explanation: The transaction is a routine part of the company's compensation plan and shows director confidence, but it is not a major event.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of shares in lieu of cash compensation helps the company conserve cash.

Management Comments

• The shares are issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.

Industry Context

This type of transaction is common for companies looking to conserve cash, especially in the biotechnology sector where funding can be volatile. It aligns director interests with shareholders.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation to conserve cash, especially during development phases.
• This is a common practice among companies of similar size and stage of development as AIM ImmunoTech.
• The use of stock in lieu of cash is a standard practice to align director interests with shareholders.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment.
• The company benefits from conserving cash by issuing shares instead of cash compensation.

Key Dates

Keywords

AIM ImmunoTech, Director, Share Acquisition, Compensation, Cash Conservation Plan, Stock Ownership, Form 4